New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export AZN’s income statement to Excel — free account
AstraZeneca PLC
AZNHealthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +23.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
175.60
0.15
+0.09%
Follow AZN
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was 12.3% in Q3 FY26, against a low of 11.7% in Q2 FY26.
ROEROIC
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | 22.8% | 23.5% | 22.0% | 22.6% |
| ROIC | 12.2% | 12.5% | 11.7% | 12.3% |
Debt
Net debt is 3.88× a year’s EBITDA. Debt is 0.61× equity, against 0.68× in Q1 FY26.
Debt / equityNet debt / EBITDA
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Debt / equity | 0.6× | 0.7× | 0.6× | 0.6× |
| Net debt / EBITDA | 4.9× | 4.3× | 4.8× | 3.9× |
Cash cycle, in days
Customers pay in 96 days, inventory is held 223 days and suppliers are paid in 764. Suppliers fund 445 days of working capital.
Days to pay suppliersDays to be paid
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Cash cycle | −541 | −434 | −429 | −445 |
| Days to pay suppliers | 868 | 742 | 751 | 764 |
| Days to be paid | 102 | 92 | 95 | 96 |
Per share, from Q4 FY25
Since Q4 FY25, per share: free cash flow has fallen 28.3%; revenue has grown 6.07%; book value has grown 6.22%.
Free cash flowRevenueBook value
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Free cash flow | 1.0× | 0.9× | 0.7× | 0.7× |
| Revenue | 1.0× | 1.0× | 1.0× | 1.1× |
| Book value | 1.0× | 1.0× | 1.0× | 1.1× |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
9 | 9 | 9 | 7 |
| 22.83% | 23.47% | 21.95% | 22.56% | ||
| 9.38% | 9.43% | 9.15% | 9.41% | ||
ROIC |
12.15% | 12.48% | 11.67% | 12.31% | |
Return on Tangible Assets |
92.38% | 102.21% | 104.18% | 77.43% | |
Average Days of Receivables |
101.50 | 91.58 | 95.10 | 95.83 | |
Free Cash Flow per Share |
5.69 | 5.13 | 4.04 | 4.08 | |
Free Cash Flow |
8,819.00 | 7,939.00 | 6,265.00 | 6,333.00 | |
Capital Expenditures |
(5,756.00) | (6,282.00) | (7,435.00) | (6,899.00) | |
| Other line items | |||||
Cash ROIC |
10.71% | 9.11% | 7.38% | 6.93% | |
Accounts Receivable Turnover |
3.77 | 4.03 | 3.94 | 3.96 | |
Accounts Payable Turnover |
0.45 | 0.49 | 0.47 | 0.46 | |
Inventory Turnover |
1.80 | 1.78 | 1.66 | 1.67 | |
Average Days of Payables |
867.79 | 742.03 | 751.43 | 763.76 | |
Days of Inventory on Hand |
225.08 | 216.63 | 227.53 | 223.02 | |
Tax Rate |
(0.17) | (0.20) | (0.17) | (0.17) | |
Research and Development Expense of Revenue |
24.23% | 24.10% | 24.56% | 24.53% | |
Selling, General and Administrative Expense of Revenue |
34.92% | 34.66% | 35.42% | 34.88% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
8.11 | 8.24 | 8.06 | 8.31 | |
Operating CF/Net income |
1.43 | 1.37 | 1.31 | 1.20 | |
Depreciation/Fixed assets |
0.44 | 0.44 | 0.47 | 0.46 | |
Capex/Depreciation |
(1.00) | (1.08) | (1.17) | (1.08) | |
Revenue per Share |
37.92 | 39.02 | 39.57 | 40.22 | |
Operating CF per Share |
9.41 | 9.18 | 8.83 | 8.53 | |
Capex per Share |
(3.72) | (4.06) | (4.79) | (4.45) | |
Capex to Sales |
0.10 | 0.10 | 0.12 | 0.11 |
Columns are period end dates · fundamentals updated Nov 18, 2026